Rohit Sood
Executive Vice President, COMPLETE Commercialization
专长:
Rohit is helping EVERSANA disrupt the life sciences industry with innovative commercialization solutions. As a strategy and operations professional, he has served as both an advisor and global strategy leader, driving top-line business growth and identifying significant operational efficiencies in PE-backed, startup and publicly listed organizations. He has advised senior management and CEOs of global life sciences companies on critical topics, including therapeutic area growth strategy, R & D, licensing, go-to-market approaches, launch/commercial excellence and commercial models.
Rohit holds an MBA from Rutgers Business School and an MS in telecommunications from Pace University.
Articles by Rohit Sood
EVERSANA™ COMPLETE Commercialization – Executing on 4 Key Performance Indicators
EVERSANA’s Rohit Sood, Executive Vice President, COMPLETE Commercialization shares the four key performance indicators we focus on with every EVERSANA COMPLETE Commercialization program – Speed, Agility, Consistency and Risk Management. Check out our whitepaper, CHALLENGING TRADITION: The argument for integrated commercialization to improve operational agility, to learn more about what occurs when pharmaceutical companies: lean into […]
David and Goliath: How Can First-Time Launchers Avoid Failure and Beat Big Pharma Launches
A first-time pharma launch sounds exciting……but it’s demanding. Not everybody can handle it. Want to learn how to succeed? In this episode of Pharma Launch Secrets, podcast host Bozidar Jovicevic, CEO of Evermed, is joined by Rohit Sood, Executive Vice President at EVERSANA to discuss: Why has the number of 1st-time launchers increased threefold over […]
WEBINAR: A Pivotal Shift in Life Sciences Industry Across R&D and Commercial: A Conversation with the Experts
The life sciences pipeline is evolving from small molecules to biologics and cell and gene therapy, and there are currently more than 900 therapies in clinical trials. As competition rises, manufacturers also need to manage the reality that the cost of research and development has doubled as ROI reduces from 10% to 2%. In this […]
Webinar: Next Generation Commercial Innovation: Moving from Promise to Practice
As pharma continues to evolve, commercialization models must evolve also. In this PharmaVOICE webinar, EVERSANA’s Rohit Sood, EVP, COMPLETE Commercialization, and Resverlogix’s CEO Donald J. McCaffrey discuss why pharma companies are focusing on new commercial models that are agile and built on operational excellence and renewable infrastructure to recognize resource and cost benefit. While “innovative” […]
CHALLENGING TRADITION: The argument for integrated commercialization to improve operational agility
Today’s economics simply do not support building commercial capabilities from scratch, only to dismantle that infrastructure until the next need arrives. Manufacturers will spend approximately $200 million of commercialization costs over three years leading up to the launch of their product, yet 66% of drugs do not meet launch expectations. In an era of specialty and […]